Zealand Pharma CEO before possible approval: We can take major leap
These weeks, Zealand Pharma is on the cusp of getting a crucial FDA approval. If the firm successfully attains this, it may transform the company, according to CEO Emmanuel Dulac.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN
Within the next two weeks, biotech firm Zealand Pharma might get hold of its first own approval. The US Food and Drug Administration (FDA) will present its evaluation on the firm's rescue pen for treating acute low blood sugar in diabetes patients before March 27.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Zealand Pharma disappoints with diabetes drug in phase III
For subscribers
